Marijn is founder and chairman of Novalis LifeSciences LLC, an investment & advisory firm for the Life Science industry that he founded in 2017. He served as CEO of Bayer AG in Germany and CEO of Thermo Fisher Scientific in USA. He started his career in 1985 as a research scientist at General Electric’s Corporate R&D Center in New York.
Kenneth ChienCo-Founder of Moderna
Ken is Co-Founder of Moderna Therapeutics, with over three decades of experience in biotechnology, working with Genentech, AZ, Roche, Pfizer, Pictet Biotech Fund, etc. He is currently a senior advisor & business partner with EQT, the leading private equity group in Europe. By realizing the essential and limiting role of DNA templates for the large-scale generation of mRNA vaccines, he played a key role in their acquisition of Aldevron, which lead to the eventual sale in 2021. Trained as a physician-scientist , Ken is a third generation Harvard alumnus ('73) and was formerly the recipient of the Sanders Endowed Chair in the Stem Cell and Regenerative Biology Department at Harvard University. In 2013, he received a Presidential appointment as a Distinguished Professor of the Swedish Research Council and has received several awards for his work at the intersection of biotechnology and Cardiovascular Medicine, including election into the Norwegian Academy of Sciences, Austrian Academy of Sciences, and an honorary Doctor of Science from the University of Edinburgh.
Bernard SagaertChief Executive Officer
Bernard comes with extensive operational and strategic experience in the pharmaceutical and life sciences industry. He has expertise in manufacturing & distribution, and has an extensive operational background, both in companies and as consultant. He is a pharmacist from the University of Leuven, Belgium and has obtained the qualification of Qualified Person. He was a former QA & Supply Chain Director at Mylan in Belgium, and VP QA EMEAA at Sterigenics, a Sotera company.
John de KoningBoard Member
John is a Partner at EQT Life Sciences, formerly LSP. He currently serves on the boards of etherna, ONWARD Medical, VarmX, Visus Therapeutics and Xilis. He also served on the boards of other companies, such as argenx, Merus, BMEYE (acquired by Edwards Lifesciences) and Prosensa (acquired by BioMarin).
Kenneth WilsBoard Member
Kenneth is an all-round finance & venture capital professional with a passion for life sciences and healthcare. In 2007, he joined PMV, where he was primarily active as seed and early stage venture capital provider to innovative start-ups, with a focus on life sciences and healthcare. He also served as board member in several successful technology start-ups and funds.
Tony de FougerollesBoard Member
Antonin (Tony) de Fougerolles has an extensive background in mRNA and more specifically LNPs through his roles at Moderna and Alnylam. With nearly 25 years’ experience in building out drug pipelines, he has played a key role in successfully advancing three new drug modalities to market (mRNA, RNAi, single domain antibodies) and in helping build several multi-billion-dollar companies from start-up stage He is currently the CEO of Evox Therapeutics.
Phil ChaseBoard Member
Phil is currently CEO of Adimab, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies. Prior to Adimab, Phil held positions at various biotechnology companies, including serving as the General Counsel at Alnylam Pharmaceuticals and as Chief Corporate Counsel at Transkaryotic Therapies, Inc. He received his J.D. degree from Columbia University School of Law and his B.A. from Colby College.
Partner with us
Driving discovery and solving challenges for our partners, enabling them to deliver cost-effective, differentiated and efficacious RNA therapeutics.